How do you pay?

How to pay the least

Ask for the cash price

Alyftrek

We didn’t find one.

  1. Ask your pharmacy for Alyftrek’s cash price, and one or two other pharmacies too.
  2. Alyftrek’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameAlyftrek
Authorized genericvanzacaftor, tezacaftor, and deutivacaftor
Regular genericvanzacaftor, tezacaftor, and deutivacaftor
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Alyftrek?
The original
–
–

Brand nameThe maker’s card

Vertex GPS Co-pay Assistance Program

Savings card from Vertex Pharmaceuticals

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a fill

The card takes up to $20,000 a year off your co-pay.

Sign up on alyftrek.com 

Or call 1-877-752-5933.

In the maker’s words

“the Vertex GPS Co-pay Assistance Program may be able to lower your co-pay to as little as $0 per fill.”

From the maker’s offer on alyftrek.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Alyftrek itself, from the same company, sold without the brand name, and usually for less. For now Alyftrek is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

ALYFTREK is a combination of deutivacaftor, a CFTR potentiator, tezacaftor, and vanzacaftor indicated for the treatment of cystic fibrosis (CF) in adult and pediatric patients aged 6 years and older who have a clinical diagnosis of CF and who have at least one variant in the CFTR gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein.

If the patient's genotype is unknown, an FDA-cleared CF genetic test should be used to confirm the presence of at least one variant in the CFTR gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein.

Source: the FDA label for Alyftrek (Vertex Pharmaceuticals Incorporated), August 26, 2026. Full label on DailyMed 

Good to know